ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Novartis picks up NASH drug

by Lisa M. Jarvis
January 2, 2017 | APPEARED IN VOLUME 95, ISSUE 1

Novartis will pay $50 million up front for access to Conatus’ pan-caspase inhibitor emricasan, a small molecule in Phase II studies to treat nonalcoholic steatohepatitis (NASH). The deal adds another drug for the fatty liver disease to Novartis’ portfolio, which already includes an FXR agonist in Phase II trials. The companies will split the costs of a Phase IIb study of emricasan; if successful, Novartis will test it in combination with an FXR agonist. As new drugs offer cures for people with hepatitis C, NASH is forecast to become the leading cause of liver transplants by 2020.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment